|
[1]
|
The Lancet. 2021: the beginning of a new era of immunisations? Lancet 2021;397(10284):1519. http://dx.doi.org/10.1016/S0140-6736(21)00900-4CrossRef
|
|
[2]
|
The Lancet Child & Adolescent Health. Vaccine hesitancy: a generation at risk. Lancet Child Adolesc Health 2019;3(5):281. http://dx.doi.org/10.1016/S2352-4642(19)30092-6CrossRef
|
|
[3]
|
Black S. The importance of active surveillance in the assessment of vaccine safety. China CDC Wkly 2019;1(2):26 − 7. http://dx.doi.org/10.46234/ccdcw2019.009CrossRef
|
|
[4]
|
World Health Organization. Global vaccine safety blueprint 2.0 background research. Geneva: World Health Organization; 2019 Jul. Report No.: WHO/MVP/EMP/SAV/2019.03. Prepared by Deloitte Consulting LLP. https://www.who.int/vaccine_safety/publications/2019_Landscape_Analysis.pdf?ua=1. [2021-07-01].https://www.who.int/vaccine_safety/publications/2019_Landscape_Analysis.pdf?ua=1 |
|
[5]
|
Crawford NW, Clothier H, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccines 2014;13(2):265 − 76. http://dx.doi.org/10.1586/14760584.2014.866895CrossRef
|
|
[6]
|
Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997;99(6):765 − 73. http://dx.doi.org/10.1542/peds.99.6.765CrossRef
|
|
[7]
|
Nguyen M, Ball R, Midthun K, Lieu TA. The Food and Drug Administration’s Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012;21(S1):291 − 7. http://dx.doi.org/10.1002/pds.2323CrossRef
|
|
[8]
|
Liu ZK, Zhang L, Yang Y, Meng RG, Fang T, Dong Y, et al. Active surveillance of adverse events following human papillomavirus vaccination: feasibility pilot study based on the regional health care information platform in the city of Ningbo, China. J Med Internet Res 2020;22(6):e17446. http://dx.doi.org/10.2196/17446CrossRef
|
|
[9]
|
Scheifele DW, Halperin SA, Gold R, Samson H, King A. Assuring vaccine safety: a celebration of 10 years of progress with the IMPACT project. Paediatr Child Health 2002;7(9):645 − 8. http://dx.doi.org/10.1093/pch/7.9.645CrossRef
|
|
[10]
|
Baker MA, Lieu TA, Li LL, Hua W, Qiang YD, Kawai AT, et al. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol 2015;181(8):608 − 18. http://dx.doi.org/10.1093/aje/kwu322CrossRef
|
|
[11]
|
Chen Y, Zhang JL, Chu XH, Xu YL, Ma FB. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol 2020;35(4):363 − 70. http://dx.doi.org/10.1007/s10654-019-00596-1CrossRef
|
|
[12]
|
Pillsbury A, Cashman P, Leeb A, Regan A, Westphal D, Snelling T, et al. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Euro Surveill 2015;20(43):30050. http://dx.doi.org/10.2807/1560-7917.ES.2015.20.43.30050CrossRef
|
|
[13]
|
Yang ZN, Zhao YY, Li L, Gao HD, Cai Q, Sun XX, et al. Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use. Chin J Epidemiol 2021;42:1 − 6. http://dx.doi.org/10.3760/cma.j.cn112338-20210325-00249 (In Chinese). CrossRef
|